Welcure Drugs [WELCURE] vs Entero Healthcare [ENTERO] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Welcure Drugs & Pharmaceuticals Ltd. wins in 10 metrics, Entero Healthcare Solutions wins in 8 metrics, with 0 ties. Welcure Drugs & Pharmaceuticals Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Welcure Drugs & Pharmaceuticals Ltd. | Entero Healthcare Solutions | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 1.30 | 48.93 | Welcure Drugs & Pharmaceuticals Ltd. |
| Price-to-Book Ratio | 0.28 | 3.11 | Welcure Drugs & Pharmaceuticals Ltd. |
| Debt-to-Equity Ratio | 91.72 | 24.63 | Entero Healthcare Solutions |
| PEG Ratio | 0.01 | 5.72 | Welcure Drugs & Pharmaceuticals Ltd. |
| EV/EBITDA | 2.81 | 28.71 | Welcure Drugs & Pharmaceuticals Ltd. |
| Profit Margin (TTM) | 12.21% | 1.87% | Welcure Drugs & Pharmaceuticals Ltd. |
| Operating Margin (TTM) | 12.24% | 3.40% | Welcure Drugs & Pharmaceuticals Ltd. |
| EBITDA Margin (TTM) | 12.24% | 3.40% | Welcure Drugs & Pharmaceuticals Ltd. |
| Return on Equity | 2.12% | 5.36% | Entero Healthcare Solutions |
| Return on Assets (TTM) | 0.81% | 3.51% | Entero Healthcare Solutions |
| Free Cash Flow (TTM) | $-2.22B | $-881.80M | Entero Healthcare Solutions |
| 1-Year Return | -72.38% | -0.41% | Entero Healthcare Solutions |
| Price-to-Sales Ratio (TTM) | 0.10 | 0.91 | Welcure Drugs & Pharmaceuticals Ltd. |
| Enterprise Value | $1.26B | $58.10B | Entero Healthcare Solutions |
| EV/Revenue Ratio | 0.34 | 0.97 | Welcure Drugs & Pharmaceuticals Ltd. |
| Gross Profit Margin (TTM) | N/A | 10.11% | N/A |
| Revenue per Share (TTM) | $2 | $1,383 | Entero Healthcare Solutions |
| Earnings per Share (Diluted) | $0.23 | $25.83 | Entero Healthcare Solutions |
| Beta (Stock Volatility) | -1.80 | -0.79 | Welcure Drugs & Pharmaceuticals Ltd. |
Welcure Drugs & Pharmaceuticals Ltd. vs Entero Healthcare Solutions Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Welcure Drugs & Pharmaceuticals Ltd. | -3.70% | -6.90% | -3.57% | -10.00% | -52.63% | -35.71% |
| Entero Healthcare Solutions | -2.17% | -10.21% | -6.57% | 12.44% | 9.42% | 2.02% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Welcure Drugs & Pharmaceuticals Ltd. | -72.38% | -21.62% | 26.09% | 141.67% | 93.33% | -45.28% |
| Entero Healthcare Solutions | -0.41% | 4.02% | 4.02% | 4.02% | 4.02% | 4.02% |
Performance & Financial Health Analysis: Welcure Drugs & Pharmaceuticals Ltd. vs Entero Healthcare Solutions
| Metric | WELCURE | ENTERO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹370.78M | ₹54.69B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 13,383,901 | 76,067 |
| 90 Day Avg. Volume | 10,165,552 | 89,093 |
| Last Close | ₹0.26 | ₹1,127.40 |
| 52 Week Range | ₹0.23 - ₹1.44 | ₹944.00 - ₹1,390.00 |
| % from 52W High | -82.00% | -18.89% |
| All-Time High | ₹25.00 (Sep 19, 2005) | ₹1,584.25 (Nov 04, 2024) |
| % from All-Time High | -98.96% | -28.84% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -1.00% | 0.26% |
| Quarterly Earnings Growth | 1.57% | 0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.02% |
| Operating Margin (TTM) | 0.12% | 0.03% |
| Return on Equity (TTM) | 0.02% | 0.05% |
| Debt to Equity (MRQ) | 91.72 | 24.63 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1.09 | ₹405.79 |
| Cash per Share (MRQ) | ₹0.02 | ₹37.37 |
| Operating Cash Flow (TTM) | ₹-2,249,340,000 | ₹-1,784,990,000 |
| Levered Free Cash Flow (TTM) | ₹21.70M | ₹948.20M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Welcure Drugs & Pharmaceuticals Ltd. vs Entero Healthcare Solutions
| Metric | WELCURE (Apr 26, 2026) | ENTERO (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 1.30 | 48.93 |
| Forward P/E | N/A | 28.42 |
| PEG Ratio | 0.01 | 5.72 |
| Price to Sales (TTM) | 0.10 | 0.91 |
| Price to Book (MRQ) | 0.28 | 3.11 |
| Market Capitalization | ||
| Market Capitalization | ₹370.78M | ₹54.69B |
| Enterprise Value | ₹1.26B | ₹58.10B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.34 | 0.97 |
| Enterprise to EBITDA | 2.81 | 28.71 |
| Risk & Other Metrics | ||
| Beta | -1.80 | -0.79 |
| Book Value per Share (MRQ) | ₹1.09 | ₹405.79 |
Financial Statements Comparison: Welcure Drugs & Pharmaceuticals Ltd. vs Entero Healthcare Solutions
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | WELCURE (2025) | ENTERO (2025) |
|---|---|---|
| Revenue/Sales | 245.50M | 50.65B |
| Cost of Goods Sold | 205.03M | 46.09B |
| COGS % of Revenue | 83.5% | 91.0% |
| Gross Profit | 40.47M | 4.56B |
| Gross Margin | 16.5% | 9.0% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 9.61M | 1.42B |
| Operating Margin | 3.9% | 2.8% |
| EBITDA | -9.41M | 2.07B |
| EBITDA Margin | -3.8% | 4.1% |
| Pre-Tax Income | 27.80M | 1.39B |
| Pre-Tax Income % of Revenue | 11.3% | 2.7% |
| Income Tax | 6.10M | 313.05M |
| Income Tax % of Revenue | 2.5% | 0.6% |
| Net Income (Profit) | 21.70M | 1.07B |
| Profit Margin | 8.8% | 2.1% |
Balance Sheet & Liquidity Metrics
| Metric | WELCURE (2025) | ENTERO (2025) |
|---|---|---|
| Cash & Equivalents | 1.28M | 2.29B |
| Total Current Assets | 1.82B | 20.76B |
| Total Current Assets % of Revenue | 741.9% | 41.0% |
| Total Current Liabilities | 412.69M | 8.45B |
| Total Current Liabilities % of Revenue | 168.1% | 16.7% |
| Long-Term Debt | 1.23B | 670.18M |
| Long-Term Debt % of Revenue | 501.8% | 1.3% |
| Total Shareholders Equity | 1.03B | 17.70B |
| Retained Earnings | -100.79M | 638.28M |
| Retained Earnings % of Revenue | -41.1% | 1.3% |
| Property, Plant & Equipment | N/A | 1.64B |
Cash Flow Statement Comparison
| Metric | WELCURE (2025) | ENTERO (2025) |
|---|---|---|
| Operating Cash Flow | -2.25B | -1.78B |
| Operating Cash Flow % of Revenue | -916.2% | -3.5% |
| Capital Expenditures | -170,000 | -103.73M |
| Free Cash Flow | -2.22B | -881.80M |
| FCF Margin | -904.5% | -1.7% |
| Debt Repayment | N/A | -458.22M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | WELCURE | ENTERO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 1.24B | 43.51M |
| Float Shares | 6.63M | 14.37M |
| % Held by Insiders | 85.74% | 65.97% |
| % Held by Institutions | 0.00% | 12.55% |
| % Held by Public | 14.26% | 21.48% |
Dividend Analysis & Yield Comparison: Welcure Drugs & Pharmaceuticals Ltd. vs Entero Healthcare Solutions
| Metric | WELCURE | ENTERO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |